ORIENT BIO Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021
November 15, 2021 at 04:20 am
Share
ORIENT BIO Inc. reported earnings results for the second quarter and six months ended September 30, 2021. For the second quarter, the company reported sales was KRW 14,479.14 million compared to KRW 12,015.06 million a year ago. Net loss was KRW 221.05 million compared to KRW 9,073.28 million a year ago. Basic loss per share from continuing operations was KRW 2 compared to KRW 81 a year ago. Diluted loss per share from continuing operations was KRW 2 compared to KRW 81 a year ago. Basic loss per share was KRW 2 compared to KRW 81 a year ago.
For the six months, sales was KRW 435.11 million compared to KRW 686.3 million a year ago. Net income was KRW 2,469.51 million compared to net loss of KRW 9,455.16 million a year ago. Basic earnings per share from continuing operations was KRW 21 compared to basic loss per share from continuing operations of KRW 88 a year ago. Diluted earnings per share from continuing operations was KRW 21 compared to diluted loss per share from continuing operations of KRW 88 a year ago. Basic earnings per share was KRW 21 compared to basic loss per share of KRW 88 a year ago.
ORIENT BIO Inc. is a Korea-based company engaged in the biotechnology area. The Company produces and supplies laboratory animals, including mice, rats, guinea pigs, hamsters, specific pathogen free (SPF) rabbits, beagles and others. It also provides contract research organization (CRO) services, including CRO safety assessment and CRO new drug development services; medical and library equipment, such as barrier systems, and support services such as rodent surgery services, laboratory diagnostics services, transgenic services, genetic testing services and other services. In addition, along with its subsidiaries, the Company provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines.
ORIENT BIO INC. 
